Chris N. Barnes

Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator.

M. F. O'Rourke, D. Baron, Anne Keogh et al. · Circulation · 1988 · 229 citations · Full text

Medicine, Cardiology, Pharmacology +14

Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial

Lisa Lancaster, Vincent Cottin, Murali Ramaswamy et al. · American Journal of Respiratory and Critical Care Medicine · 2024 · 65 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +10

Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies

Kyriakie Sarafoglou, Chris N. Barnes, Michael Huang et al. · The Journal of Clinical Endocrinology & Metabolism · 2021 · 39 citations · Full text

Life Sciences, Endocrinology, Pharmacotherapy +17

Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease

James F. Donohue, Edward Kerwin, Sanjay Sethi et al. · Respiratory Medicine · 2019 · 38 citations

Medicine, Pharmacology, Pharmacotherapy +14

Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double‐blind, randomised, placebo‐controlled, phase 2 study

Braden Kuo, Chris N. Barnes, Deanna D. Nguyen et al. · Alimentary Pharmacology & Therapeutics · 2021 · 32 citations

Pharmacy, Pharmacology, Pharmacotherapy +15